NASDAQ: SVRA - Savara Inc.

Yield per half year: -33.57%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Savara Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Savara Inc.

Savara Inc. работает как компания, специализирующаяся на лечении сиротских заболеваний легких. Его ведущий кандидат в продукт включает Молградекс, ингаляционный колониестимулирующий фактор гранулоцитов-макрофагов, который находится на стадии разработки III фазы для лечения аутоиммунного легочного альвеолярного протеиноза; Стадия развития фазы IIa для лечения нетуберкулезной микобактериальной (NTM) инфекции легких; и на стадии разработки фазы IIa для лечения инфекции легких NTM у людей, живущих с муковисцидозом.

more details
Компания также разрабатывает AeroVanc, ингаляционный ванкомицин, который находится на стадии разработки III для лечения метициллин-резистентной инфекции легких Staphylococcus aureus у людей, живущих с муковисцидозом. Штаб-квартира Savara Inc. находится в Остине, штат Техас.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2017-06-01
ISIN US8051111016
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.savarapharma.com
Цена ао 2.79
Change price per day: +7.31% (2.6)
Change price per week: +7.31% (2.6)
Change price per month: +1.45% (2.75)
Change price per 3 month: -16.72% (3.35)
Change price per half year: -33.57% (4.2)
Change price per year: -40.13% (4.66)
Change price per 3 year: +117.97% (1.28)
Change price per 5 year: +50% (1.86)
Change price per 10 year: 0% (2.79)
Change price per year to date: -13.62% (3.23)
All parameters

Underestimation

Title Value Grade
P/S 119770 1
P/BV 5.77 2
P/E 0 0
EV/EBITDA -13.53 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -30.8 0
ROE, % -38.97 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.4428 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -83.4 0
Yield Ebitda, % 136.53 10
Yield EPS, % -89.87 0
Total: 2.4
More

Institutions Volume Share, %
NEA Management Company, LLC 24471264 17.71
Bain Capital Life Sciences Investors, LLC 14232751 10.3
Tcg Crossover Management, Llc 10000000 7.24
Jennison Associates LLC 8815358 6.38
Adage Capital Partners GP L.L.C. 7637930 5.53
Blackrock Inc. 7261530 5.26
Farallon Capital Management Llc 6255406 4.53
Vanguard Group Inc 5914947 4.28
Frazier Life Sciences Management, L.P. 4000000 2.9
VR Adviser, LLC 3500000 2.53

ETFShare, %Profitability for 1 year, %Dividends, %
Virtus LifeSci Biotech Clinical Trials ETF 0.87584 63.04 0.33
iShares Micro-Cap ETF 0.13124 17.09 1.54048
Future Tech ETF 0.07171 426.34 0.8416
Principal Healthcare Innovators ETF 0.07171 618.5 0.8416
Invesco Nasdaq Biotechnology ETF 0.06179 28.58 0.8565
Vanguard U.S. Momentum Factor ETF 0.06 30.05 1.05834
Direxion Daily S&P Biotech Bull 3x Shares 0.05075 4067.92 0.25924
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.04967 31.36 1.41955
iShares ESG Aware MSCI USA Small-Cap ETF 0.04808 18.09 1.49366
Nuveen ESG Small-Cap ETF 0.04401 13.91 1.41019
ProShares Ultra Nasdaq Biotechnology 0.04077 51.7 0.85651
iShares Russell 2000 Growth ETF 0.03057 38.04 0.6026
iShares Morningstar Small-Cap Growth ETF 0.02155 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.02155 587.89 0.72598
Vanguard Russell 2000 Growth ETF 0.02 23.05 0.60264
Vanguard Russell 2000 ETF 0.02 17.16 1.48801
iShares Morningstar Small-Cap ETF 0.01078 391.25 1.60498
iShares Morningstar Small-Cap ETF 0.01078 30.1 1.60498
ProShares UltraPro Russell2000 0.00941 89.82 1.47873
Fidelity MSCI Health Care Index ETF 0.00642 3 1.46057
Humankind US Stock ETF 0.00319 18.81 1.99919
ProShares Hedge Replication ETF 0.00262 5.92 1.47892
iShares Russell 3000 ETF 0.00127 24.83 1.43482
Avantis U.S Small Cap Equity ETF 0.00008 27.77 1.68271
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.07267.591.17



Head Job title Payment Year of birth
Ms. Anne Erickson Chief Business Officer N/A 1972 (53 years)
Brian Maurer Head of Clinical Operations N/A
Mr. Charles LaPree Senior Vice President of Global Regulatory Affairs & Quality Assurance N/A
Dr. Peter Clarke Ph.D. Executive Vice President of Global Technical Operations N/A 1960 (65 years)
Mr. David L. Lowrance CPA CFO, Chief Administrative Officer & Secretary 613.75k 1968 (57 years)
Dr. Raymond Dennis Pratt FACP, M.D. Chief Medical Officer 91.89k 1951 (74 years)
Mr. Robert Lutz M.B.A. Chief Operating Officer N/A 1970 (55 years)
Mr. Scott L. Wilhoit Executive Vice President of Global Commercial N/A 1963 (62 years)
Mr. Matthew Pauls J.D., M.B.A. Chairman & CEO 894.54k 1971 (54 years)
Ms. Kate McCabe J.D. Senior VP & General Counsel

Address: United States, Austin, TX , Building III - open in Google maps, open in Yandex maps
Website: http://www.savarapharma.com